Basilea Enters a Global Collaboration with Johnson & Johnson's Affiliate Cilag AG International for Basilea's Phase III, First-in-Class Antibiotic Ceftobiprole (BAL5788)
February 03, 2005 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 3rd February 2005
Basilea Pharmaceutica AG announced today that it has entered into an exclusive worldwide agreement with Cilag AG International, a Johnson & Johnson...
Basilea's Novel Broad-Spectrum Oral and Intravenous Anti-Fungal Moves into Phase II
January 04, 2005 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 4th January 2005
Basilea Pharmaceutica AG announces the start of its phase II program for BAL8557 in oesophageal candidiasis. BAL8557 is a novel anti-fungal intended...
Beginn der Phase-II-Studien für das neue orale und intravenöse Breitspektrum-Antimykotikum von Basilea
January 04, 2005 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 4. Januar 2005
Basilea Pharmaceutica AG gibt den Start des Phase-II Programms für BAL8557 bei Speiseröhren-Candidiasis bekannt. BAL8557 ist ein neues Antimykotikum, das bei schweren...
U.S. Federal Trade Commission erhebt keinen Einwand gegen potentielle Zusammenarbeit zwischen Basilea und Johnson & Johnson
December 15, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 15. Dezember 2004
Die U.S. Federal Trade Commission hat bekanntgegeben, dass sie bezüglich einer von Johnson & Johnson und Basilea Pharmaceutica AG eingereichten Meldung eine...
U.S. Federal Trade Commission Does Not Oppose a Potential Collaboration Between Basilea and Johnson & Johnson
December 15, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 15th December 2004
The U.S. Federal Trade Commission recently announced that it granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust...
Basilea startet Phase-III-Studien mit Ceftobiprol (BAL5788) - dem ersten Vertreter einer neuen Klasse von Antibiotika
November 04, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 4. November 2004
Basilea Pharmaceutica AG gibt den Beginn ihres internationalen Phase-III-Programms bei komplizierten Infektionen der Haut und Weichteile, verursacht durch...
Basilea's First-In-Class Antibiotic Ceftobiprole (BAL5788) Moves into Phase III
November 04, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 4th November 2004
Basilea Pharmaceutica AG announces the start of its international phase III program for ceftobiprole (BAL5788), a novel broad spectrum, first-in-class...
Basilea's First-In-Class Antibiotic Ceftobiprole (BAL5788) Unaffected by Resistance and Novel Once-Daily Antifungal (BAL8557) Active Against Resistant Aspergillus
November 02, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 2nd November 2004
Basilea Pharmaceutica AG presents sixteen posters at the 44th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in...
Ceftobiprol (BAL5788), erstes Antibiotikum von Basilea einer neuen Präparateklasse, ist nicht von Resistenz betroffen - BAL8557, neues Mittel gegen Pilzinfektionen zur einmal täglichen Verabreichung, ist wirksam gegen resistente Keime von Aspergillus
November 02, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 2. November 2004
Basilea Pharmaceutica AG präsentiert 16 Poster an der 44. International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington D.C., USA. ...
Basilea's BAL4079 Moves into Phase III
October 28, 2004 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, 28 October 2004
Basilea announced today the enrolment of the first patients into its phase III program investigating the efficacy and safety of BAL4079 (alitretinoin)...